Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common diabetes drug combo help those with cancer history?

NCT ID NCT07033585

Disease control Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether a combination of dapagliflozin, saxagliptin, and metformin can help control blood sugar in 600 adults with type 2 diabetes who have controlled cancers. Participants take the drugs by mouth for at least 90 days. Researchers measure blood sugar and insulin levels to see how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of dapagliflozin, saxagliptin, and metformin taken by mouth
What this could lead to
If it works, this could offer a safe and effective way to manage blood sugar in people with type 2 diabetes who also have controlled cancers.
What could go wrong
This is an early-stage trial, so the combination may not prove more effective than standard care. Participants may also face side effects from the drugs, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Select 600 type 2 diabetes patients with controlled cancers. * Dosage Duration at least 90 days Inclusion Criteria: * 1\. Clinical diagnosis of type 2 diabetes * 2\. Controlled cancers * 3\. Suitable for enough blood-drawing * 4\. Random and double blind * 5\. Measurable disease * 6\. Adequate organ functions * 7\. Adequate performance status * 8\. Age 24 years old and over * 9\. Sign an informed consent form * 10\. Receive blood-drawing Exclusion Criteria: * 1\. Uncontrolled cancers * 2\. Pregnancy * 3\. Breast-feeding * 4\. The patients with other serious intercurrent illness or infectious diseases * 5\. The participating patients have serious side effects. * 6\. Serious Allergy to Drugs * 7\. Thrombus or Bleed Tendency * 8\. Serious Risks or Serious Adverse Events of the drug product * 9\. The prohibition of drug products * 10\. Have no therapeutic effects

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701

    Rockville, Maryland, 20853, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.